Chemomab Therapeutics (CMMB) Change in Receivables (2018 - 2019)
Chemomab Therapeutics' (CMMB) quarterly Change in Receivables came in at -$3.8 million in Q4 2019, down 163.99% YoY from $5.9 million in Q4 2018, and down 977.49% on a QoQ basis from -$351000.0 in Q3 2019.
Chemomab Therapeutics (CMMB) Change in Receivables (2018 - 2019) Analysis & Trends
Chemomab Therapeutics (CMMB) has 2 years of Change in Receivables data on file, last reported at -$3.8 million in Q4 2019.
- Quarterly Change in Receivables fell 163.99% year-over-year to -$3.8 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was -$724000.0 (changed N/A YoY) and the FY2019 annual result came in at -$2.3 million, down 165.93% from the prior year.
- Change in Receivables fell to -$3.8 million in Q4 2019, from -$351000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $5.9 million in Q4 2018 to a low of -$3.8 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -3.78 Mn |
| Dec 31, 2019 | -3.78 Mn |
| Sep 30, 2019 | -351,000.00 |
| Sep 30, 2019 | -351,000.00 |
| Dec 31, 2018 | 5.91 Mn |
| Dec 31, 2018 | 5.91 Mn |
| Sep 30, 2018 | -2.50 Mn |
| Sep 30, 2018 | -2.50 Mn |